Bristol Myers Squibb (NYSE:BMY – Get Free Report) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Wednesday, Zacks reports. Zacks Research also issued estimates for Bristol Myers Squibb’s Q3 2027 earnings at $1.56 EPS, FY2027 earnings at $6.24 EPS, Q1 2028 earnings at $1.48 EPS, Q2 2028 earnings at $1.38 EPS and FY2028 earnings at $5.23 EPS.
Several other equities analysts have also recently issued reports on the stock. Cantor Fitzgerald restated a “neutral” rating and issued a $59.00 price target (up from $54.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. HSBC reissued a “hold” rating and issued a $65.00 price objective (up from $60.00) on shares of Bristol Myers Squibb in a research note on Thursday, September 10th. Guggenheim reaffirmed a “buy” rating and set a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Bank of America cut their target price on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a report on Friday, July 10th. Finally, Raymond James Financial began coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a “strong-buy” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $67.06.
Check Out Our Latest Research Report on Bristol Myers Squibb
Bristol Myers Squibb Stock Up 0.6%
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same quarter in the previous year, the company posted $1.46 EPS. Bristol Myers Squibb’s quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities analysts predict that Bristol Myers Squibb will post 6.95 EPS for the current fiscal year.
Insider Activity
In related news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.05% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Bristol Myers Squibb
Institutional investors have recently added to or reduced their stakes in the business. KCM Investment Advisors LLC raised its stake in shares of Bristol Myers Squibb by 0.8% during the 4th quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company’s stock worth $1,126,000 after purchasing an additional 174 shares in the last quarter. Sandy Cove Advisors LLC increased its holdings in Bristol Myers Squibb by 4.7% in the second quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company’s stock worth $227,000 after buying an additional 176 shares during the last quarter. Investment Research Partners LLC raised its position in Bristol Myers Squibb by 1.4% during the fourth quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company’s stock valued at $708,000 after acquiring an additional 179 shares in the last quarter. REAP Financial Group LLC lifted its stake in Bristol Myers Squibb by 26.1% in the fourth quarter. REAP Financial Group LLC now owns 879 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 182 shares during the last quarter. Finally, Key Financial Inc grew its position in Bristol Myers Squibb by 2.4% in the first quarter. Key Financial Inc now owns 7,939 shares of the biopharmaceutical company’s stock worth $482,000 after acquiring an additional 183 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.
Key Headlines Impacting Bristol Myers Squibb
Here are the key news stories impacting Bristol Myers Squibb this week:
- Positive Sentiment: Zacks Research modestly raised its earnings forecasts for Bristol Myers Squibb, increasing estimates for third-quarter 2027 EPS to $1.56, full-year 2027 EPS to $6.24, first- and second-quarter 2028 EPS to $1.48 and $1.38, respectively, and full-year 2028 EPS to $5.23 from $5.17. The revisions suggest slightly improved expectations for the company’s future earnings. Zacks Research estimates
- Positive Sentiment: BMY was added to Zacks’ Rank #1 Strong Buy list and its Strong Buy income-stock list. The ratings may support demand for the shares, particularly because Bristol Myers Squibb offers significant cash flow and an attractive dividend profile. Zacks Strong Buy list
- Positive Sentiment: The company selected Onco360 as a restricted specialty-pharmacy provider for ZENBEXUS (iberdomide), its newly approved multiple-myeloma treatment. The distribution arrangement and clinical support could help the drug reach eligible patients during its commercial rollout. ZENBEXUS pharmacy network
- Positive Sentiment: Bristol Myers Squibb completed a Phase 1 lung-cancer combination study, providing incremental support for its immuno-oncology pipeline. Analysts also highlighted newer medicines as increasingly important in offsetting declines from mature products. Lung cancer study update
- Negative Sentiment: Despite the near-term positives, investors remain concerned about patent expirations and declines in established blockbuster products. Longer-term Zacks estimates remain below current-year expectations, underscoring the need for newer drugs such as ZENBEXUS to replace lost revenue.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.
The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.
Featured Stories
- Five stocks we like better than Bristol Myers Squibb
- 3 Space Stocks to Watch as SpaceX Reshapes the Launch Market
- Dave’s Success Has Investors Split
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
